MX363923B - Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas. - Google Patents

Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.

Info

Publication number
MX363923B
MX363923B MX2014007934A MX2014007934A MX363923B MX 363923 B MX363923 B MX 363923B MX 2014007934 A MX2014007934 A MX 2014007934A MX 2014007934 A MX2014007934 A MX 2014007934A MX 363923 B MX363923 B MX 363923B
Authority
MX
Mexico
Prior art keywords
linked
treatment
composition
novedoso
pharmaco
Prior art date
Application number
MX2014007934A
Other languages
English (en)
Spanish (es)
Other versions
MX2014007934A (es
Inventor
G Traber Peter
Zomer Eliezer
A Klyosov Anatole
Chekhova Elena
Original Assignee
Galectin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Therapeutics Inc filed Critical Galectin Therapeutics Inc
Publication of MX2014007934A publication Critical patent/MX2014007934A/es
Publication of MX363923B publication Critical patent/MX363923B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MX2014007934A 2011-12-28 2012-09-14 Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas. MX363923B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161580830P 2011-12-28 2011-12-28
PCT/US2012/055311 WO2013101314A1 (en) 2011-12-28 2012-09-14 Composition of novel carbohydrate drug for treatment of human diseases

Publications (2)

Publication Number Publication Date
MX2014007934A MX2014007934A (es) 2015-03-09
MX363923B true MX363923B (es) 2019-04-08

Family

ID=48698494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007934A MX363923B (es) 2011-12-28 2012-09-14 Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.

Country Status (14)

Country Link
US (9) US8871925B2 (https=)
EP (1) EP2797942B1 (https=)
JP (3) JP6133894B2 (https=)
KR (1) KR101968370B1 (https=)
CN (1) CN104245717B (https=)
AU (2) AU2012363033B2 (https=)
BR (1) BR112014015940B1 (https=)
CA (1) CA2861492C (https=)
DK (1) DK2797942T3 (https=)
ES (1) ES2699386T3 (https=)
IL (1) IL233313A (https=)
MX (1) MX363923B (https=)
WO (1) WO2013101314A1 (https=)
ZA (1) ZA201505849B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
ES2869884T3 (es) * 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
AU2012363033B2 (en) 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
ES2848538T3 (es) * 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
DK2900061T3 (da) 2012-09-17 2020-03-02 Galectin Therapeutics Inc Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
GB201502668D0 (en) * 2015-02-17 2015-04-01 Glycomar Ltd And Albert Bartlett & Sons Airdrie Ltd Method for isolation of polysaccharides
FR3036943A1 (fr) * 2015-06-02 2016-12-09 Echosens Dispositif non invasif de detection de lesion hepatique
JP7086008B2 (ja) * 2016-03-04 2022-06-17 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用
US20190365790A1 (en) * 2017-01-13 2019-12-05 Sivanaray Inc. Compounds, Compositions and Methods for Prevention or Treatment of Liver and Lipid-related Conditions
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
US11524037B2 (en) 2017-09-08 2022-12-13 Evelo Biosciences, Inc. Bacterial extracellular vesicles
US20210138080A1 (en) 2018-06-29 2021-05-13 Glykos Biomedical Oy Conjugates
DE102019003442A1 (de) 2019-05-15 2020-11-19 Ilma biochem GmbH Verwendung von niedermolekularen glykosidisch gebundenen endständigen Galactosiden und Fucosiden zur Bindung von als Galectin wirkenden Toxinen im Rahmen der Behandlung von Vergiftungen, insbesondere bei Vergiftungen mit Ricin
WO2021064729A1 (en) * 2019-10-02 2021-04-08 Patchor Ltd. Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
WO2022016105A1 (en) * 2020-07-17 2022-01-20 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use
CN116211884B (zh) * 2023-02-16 2024-05-17 海孵(海南自贸区)医疗科技有限责任公司 一种鼻腔喷雾剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2132577A (en) 1934-08-28 1938-10-11 Gen Foods Corp Method of preparing pectin
US2444266A (en) 1944-03-31 1948-06-29 Us Agriculture Pectic materials and method of preparing same
US2503258A (en) 1948-01-23 1950-04-11 Us Agriculture Neutralization of pectinic acids with sodium bicarbonate
US4016351A (en) 1976-02-04 1977-04-05 Eschinasi Emile H Pectic substances with varying methoxyl content and process therefor
US4268533A (en) 1979-11-21 1981-05-19 General Foods Corporation Quick-set low methoxyl pectin composition
JPS61502124A (ja) * 1984-05-09 1986-09-25 ジ　オ−ストラリアン　ナシヨナル　ユニヴア−シテイ− 免疫応答の調節方法
US4686106A (en) 1986-06-16 1987-08-11 General Foods Corporation Pectin food product
US5071970A (en) 1988-11-23 1991-12-10 University Of Florida Process for producing pectin with a high-to-medium methoxyl content from beet pulp
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US7491708B1 (en) 1993-03-01 2009-02-17 David Platt Modified pectin
JP3360899B2 (ja) 1993-10-08 2003-01-07 日本医薬品工業株式会社 癌予防・治療剤
US5498702A (en) 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
US6632797B2 (en) 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
KR100252194B1 (ko) 1997-10-10 2000-04-15 박호군 참당귀에서분리한신규한펙틴질다당류와그분리정제방법및그의면역증강제로서의용도
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6500807B1 (en) 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US20040121981A1 (en) 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
KR100594353B1 (ko) 2002-05-28 2006-07-03 주식회사 엠디바이오알파 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물
JP2004107295A (ja) * 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization ヒスタミン遊離抑制剤
US20040223971A1 (en) 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2004091634A1 (en) * 2003-04-07 2004-10-28 Glycogenesys, Inc. Composition and uses of galectin antagonists
US20050008572A1 (en) 2003-04-29 2005-01-13 Ales Prokop Nanoparticular tumor targeting and therapy
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005095463A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
KR101074158B1 (ko) 2008-04-07 2011-10-17 재단법인 한국원자력의학원 간 보호 또는 간 질환의 예방 및 치료용 인삼다당체 조성물
US9646327B2 (en) 2011-08-09 2017-05-09 Yahoo! Inc. Disaggregation to isolate users for ad targeting
ES2869884T3 (es) 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
AU2012363033B2 (en) 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
ES2848538T3 (es) * 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
DK2900061T3 (da) * 2012-09-17 2020-03-02 Galectin Therapeutics Inc Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis

Also Published As

Publication number Publication date
AU2012363033A1 (en) 2014-07-17
BR112014015940B1 (pt) 2022-08-09
EP2797942B1 (en) 2018-10-31
ZA201505849B (en) 2017-03-26
US20230000898A1 (en) 2023-01-05
CN104245717A (zh) 2014-12-24
EP2797942A1 (en) 2014-11-05
DK2797942T3 (en) 2018-12-10
US9649327B2 (en) 2017-05-16
AU2016222423A1 (en) 2016-09-22
US9974802B2 (en) 2018-05-22
JP6133894B2 (ja) 2017-05-24
IL233313A (en) 2017-08-31
MX2014007934A (es) 2015-03-09
WO2013101314A1 (en) 2013-07-04
KR101968370B1 (ko) 2019-04-11
EP2797942A4 (en) 2015-06-03
US20150174151A1 (en) 2015-06-25
US8871925B2 (en) 2014-10-28
AU2016222423B2 (en) 2018-02-22
JP2017149976A (ja) 2017-08-31
US20170202870A1 (en) 2017-07-20
BR112014015940A8 (pt) 2021-09-28
JP2015503658A (ja) 2015-02-02
US20140350238A1 (en) 2014-11-27
CN104245717B (zh) 2017-10-24
US20180256626A1 (en) 2018-09-13
JP6415677B2 (ja) 2018-10-31
US10420793B2 (en) 2019-09-24
CA2861492C (en) 2019-09-24
ES2699386T3 (es) 2019-02-11
US20130261078A1 (en) 2013-10-03
US11413303B2 (en) 2022-08-16
KR20140143137A (ko) 2014-12-15
BR112014015940A2 (pt) 2017-06-13
CA2861492A1 (en) 2013-07-04
US8962824B2 (en) 2015-02-24
JP6262386B2 (ja) 2018-01-17
AU2012363033B2 (en) 2016-06-02
IL233313A0 (en) 2014-08-31
US20260053840A1 (en) 2026-02-26
US20210093656A1 (en) 2021-04-01
US10799525B2 (en) 2020-10-13
US20200078390A1 (en) 2020-03-12
JP2018076519A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
MX363923B (es) Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.
NZ707859A (en) Inhibitors of sodium glucose cotransporter 1
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
EA201201648A1 (ru) Стимуляторы sgc
MY169328A (en) Compositions for the treatment of dry eye
WO2013061309A3 (en) New a-prp medical device & tissue engineering composition, manufacturing machines and process
AU2010230585A8 (en) Autotaxin inhibitors
MX370853B (es) Formulaciones que contienen dapagliflozina amorfa.
IN2014DN09782A (https=)
CR20140312A (es) 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
MX390997B (es) Composicion para su uso en la promocion de la angiogenesis intestinal y de la absorcion de nutrientes y de tolerancia a la alimentacion enteral y/o en la prevencion y/o en el tratamiento de la inflamacion intestinal y/o en la recuperacion posterior a un daño o cirugia intestinal.
EP2563384A4 (en) Immunogenic compositions and methods for treating neoplasia
PH12013500892B1 (en) Composition for use in the prevention and\or treatment of skin conditions and skin diseases
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
CU20170085A7 (es) Derivados de imidazolidindiona para el tratamiento de la osteoartritis
BR112016021648A2 (pt) novos compostos
MY168759A (en) Pharmaceutical compositions comprising modified fucans and methods relating thereto
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
MY151104A (en) Novel use
PH12014502680A1 (en) Polysaccharide compositions and methods of use
BR112013026680A2 (pt) composto, método de tratamento de uma doença inflamatória e composição farmacêutica
WO2015080980A3 (en) Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.

Legal Events

Date Code Title Description
FG Grant or registration